Rachel B. Wilson

Rachel B. Wilson

Auto-generated profile, based on publicly available information

Rachel B. Wilson

Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2024 in Journal of Biological Chemistry
Verified
Journal Article
Open access
RWRachel B. Wilson
Rachel B. Wilson
AKAlexandra M. Kozlov
Alexandra M. Kozlov
HTHelia Hatam Tehrani
Helia Hatam Tehrani
JTJessica S. Twumasi-Ankrah
Jessica S. Twumasi-Ankrah
YCYun Jin Chen
Yun Jin Chen
NBNica M. Borradaile
Nica M. Borradaile
Eukaryotic elongation factor 1A1 (EEF1A1) is canonically involved in protein synthesis but also has noncanonical functions in diverse cellular processes. Previously, we identified EEF1A1 as a mediator of lipotoxicity and demonstrated that chemical inhibition of EEF1A1 activity reduced mouse liver lipid accumulation. These findings suggested a link between EEF1A1 and metabolism. Therefore, we investigated its role in regulating metabolic substrate preference. EEF1A1-deficient Chinese hamster ovary (2E2) cells displayed reduced media lactate accumulation. These effects were also observed with EEF1A1 knockdown in human hepatocyte-like HepG2 cells and in WT Chinese hamster ovary and HepG2 cells treated with selective EEF1A inhibitors, didemnin B, or plitidepsin. Extracellular flux analyses revealed decreased glycolytic ATP production and increased mitochondrial-to-glycolytic ATP production ratio in 2E2 cells, suggesting a more oxidative metabolic phenotype. Correspondingly, fatty acid oxidation was increased in 2E2 cells. Both 2E2 cells and HepG2 cells treated with didemnin B exhibited increased neutral lipid content, which may be required to support elevated oxidative metabolism. RNA-seq revealed a >90-fold downregulation of a rate-limiting glycolytic enzyme, hexokinase 2, which we confirmed through immunoblotting and enzyme activity assays. Pathway enrichment analysis identified downregulations in TNFA signaling via NFKB and MYC targets. Correspondingly, nuclear abundances of RELB and MYC were reduced in 2E2 cells. Thus, EEF1A1 deficiency may perturb glycolysis by limiting NFKB- and MYC-mediated gene expression, leading to decreased hexokinase expression and activity. This is the first evidence of a role for a translation elongation factor, EEF1A1, in regulating metabolic substrate utilization in mammalian cells.

1 October 2024 in American Journal of Physiology-Gastrointestinal and Liver Physiology
Verified
Journal Article
Open access
RWRachel B. Wilson
Rachel B. Wilson
YCYun Jin Chen
Yun Jin Chen
RZRichard Zhang
Richard Zhang
SMSiddhant Maini
Siddhant Maini
TATallulah S. Andrews
Tallulah S. Andrews
NBNica M. Borradaile
Nica M. Borradaile
Chemical inhibition of EEF1A1 decreases hepatic lipid droplet size and decreases gene expression signatures associated with liver cell types that contribute to MASLD progression. Furthermore, changes in hepatic gene expression are primarily attributable to hepatocytes and cholangiocytes. This work highlights the therapeutic potential of targeting EEF1A1 in the setting of MASLD, and the utility of RNA-Seq deconvolution to reveal valuable information about tissue cell type composition and cell type-associated gene expression from bulk RNA-Seq data.

12 June 2023
Verified
Book Chapter
Closed access
PDF file
RWRachel B. Wilson
Rachel B. Wilson
NBNica M. Borradaile
Nica M. Borradaile
Mushroom consumption is significantly associated with reduced risk of all-cause mortality. Given that cardiovascular disease is the leading cause of death worldwide, there is strong rationale to examine the potential impact of mushroom consumption on cardiovascular risk. In this chapter, we review the effects of edible mushrooms on cardiovascular protection, with emphasis on their modulation of liver lipid and glucose metabolism in relation to cardiovascular health. There is extensive evidence for benefits of mushrooms and mushroom-specific compounds on cardiovascular risk factors (e.g. plasma lipids, glucose homeostasis) and on liver lipid and glucose metabolism in preclinical models. However, only a few preclinical studies have directly studied the effects of mushrooms on atherosclerosis. Furthermore, clinical studies investigating the effects of mushrooms on cardiovascular risk factors and outcomes are lacking. In light of the potential benefits of mushrooms for cardiovascular disease suggested by preclinical work, there is a need for high-quality clinical studies to evaluate whether these benefits translate to humans.